Bridgebio Oncology TherapeutBBOT
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 31 institutions reported holding Bridgebio Oncology Therapeut (BBOT) in their 13F filings, up 2 from Q1 2024. 2 opened new positions and 0 sold out. The largest holders were Cormorant Asset Management, LP ($29.7M), BlackRock Inc. ($15.3M) and Adage Capital Partners Gp, L.L.C. ($14.3M). 3 famous investors held it, including George Soros (0.2% of Soros Fund Management's portfolio), Ken Griffin (0.0% of Citadel Advisors's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Bridgebio Oncology Therapeut
- Filed as
- HELIX ACQUISITION CORP II (Q2 2024)
- CUSIP
- G4444H101
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $3.3M |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 335,911 shares bought and 24,850 shares sold, net +311,061 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 31 holders
| Cormorant Asset Management, LP | 1.73% | No change | 2,909,000 | $29.7M |
| BlackRock Inc. | 0.00% | No change | 1,500,000 | $15.3M |
| Adage Capital Partners Gp, L.L.C. | 0.03% | No change | 1,400,000 | $14.3M |
| Citadel Advisors | 0.01% | Add +0.0% | 1,332,508 | $13.6M |
| T. Rowe Price Associates Inc. | 0.00% | No change | 1,130,677 | $11.6M |
| Millennium Management | 0.01% | Add +1.1% | 1,117,400 | $11.4M |
| Sculptor Capital LP | 0.23% | No change | 705,000 | $7.2M |
| Farallon Capital Management, L.L.C. | 0.04% | No change | 600,000 | $6.1M |
| Silverarc Capital Management, LLC | 1.26% | No change | 500,000 | $5.1M |
| Great Point Partners LLC | 0.98% | No change | 500,000 | $5.1M |
| Commodore Capital LP | 0.35% | No change | 500,000 | $5.1M |
| Perceptive Advisors LLC | 0.12% | No change | 500,000 | $5.1M |
| Soros Fund Management | 0.15% | No change | 475,000 | $4.9M |
| ADAR1 Capital Management, LLC | 0.83% | Add +0.2% | 404,138 | $4.1M |
| T. Rowe Price Investment Management, Inc. | 0.00% | No change | 400,000 | $4.1M |
| Ghost Tree Capital, LLC | 1.07% | No change | 300,000 | $3.1M |
| Laurion Capital Management LP | 0.10% | No change | 300,000 | $3.1M |
| Affinity Asset Advisors, LLC | 0.44% | No change | 250,000 | $2.6M |
| Octagon Capital Advisors LP | 0.42% | No change | 250,000 | $2.6M |
| Stempoint Capital LP | 0.60% | No change | 200,000 | $2.0M |
| Two Sigma Investments, LP | 0.00% | No change | 189,285 | $1.9M |
| Wellington Management Group LLP | 0.00% | Reduce -8.7% | 184,670 | $1.9M |
| Acuta Capital Partners, LLC | 1.53% | New | 177,836 | $1.8M |
| TD Asset Management Inc | 0.00% | New | 144,772 | $1.5M |
| Woodline Partners LP | 0.01% | Reduce -3.2% | 103,247 | $1.1M |
| Moore Capital Management, LP | 0.02% | No change | 100,000 | $1.0M |
| Walleye Capital LLC | 0.01% | Add +0.7% | 92,864 | $949K |
| Walleye Trading LLC | 0.01% | Add +0.7% | 52,236 | $534K |
| Cowen and Company, LLC | 0.01% | Reduce -7.2% | 50,511 | $516K |
| Geode Capital Management, LLC | 0.00% | No change | 10,869 | $111K |
| JPMorgan Chase & Co. | 0.00% | No change | 4 | $41 |
"% of holder's portfolio" is BBOT's weight in each manager's 13F, not the share of Bridgebio Oncology Therapeut the manager owns.